Ther­a­vance cuts 17% of staff, JAK in­hibitor pro­gram

Ther­a­vance Bio­phar­ma is cut­ting 17% of its work­force and a mid-stage in­haled JAK in­hibitor pro­gram, it an­nounced Mon­day af­ter­noon.

Ther­a­vance will be dis­con­tin­u­ing work on its in­haled JAK in­hibitor nezul­ci­tinib, which failed a tri­al in Covid-19 pa­tients in 2021. As a re­sult, Ther­a­vance said, it will be cut­ting about 17% of its staff by the end of March.

The changes fol­low Mon­day morn­ing’s call by ac­tivist in­vestor Irenic Cap­i­tal Man­age­ment, de­mand­ing changes to the board, a strate­gic re­view, and for less share-based com­pen­sa­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER